CD133+ liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling
Kwan Ho Tang(AstraZeneca (Netherlands)), Kwok Wah Chan(Queen Mary Hospital), Pak Shing Kwan(Queen Mary Hospital), Chung Mau Lo(City University of Hong Kong), Stephanie Ma(University of Hong Kong - Shenzhen Hospital), Xin‐Yuan Guan(Sun Yat-sen University), Ka‐Fai To(Chinese University of Hong Kong), Irene Oi‐Lin Ng(University of Hong Kong), Kwan Man(University of Hong Kong - Shenzhen Hospital), Terence K. Lee(Hong Kong Polytechnic University), Yuen Piu Chan(Queen Mary Hospital), Paul B.S. Lai(Chinese University of Hong Kong)
Cited by 258
Related Papers
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
|Journal of Clinical Oncology|2014|2.8k
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
|Journal of Clinical Oncology|2011|1.6k
Laparoscopic resection of rectosigmoid carcinoma: prospective randomised trial
|The Lancet|2004|895
Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments
|Proceedings of the National Academy of Sciences|2015|818